Q Fever News and Research

RSS

Household molds trigger allergic rhinitis

April showers can increase the amount of mold found inside and outside the home. Along with pollens from trees, grasses, and weeds, molds are an important trigger of allergic rhinitis, affecting nearly 40 million Americans, according to the American Academy of Allergy, Asthma & Immunology (AAAAI).

12 Apr 2004

Measles found on children travelling from China

Public Health officials have reported a laboratory-confirmed case of measles in a recently adopted child from China. Public health authorities in Washington state notified CDC, which collaborated with health officials in other states to locate other recently adopted children from China and contact their adoptive families.

12 Apr 2004

WHO update on Dengue fever in Indonesia

From 1 January to 4 April 2004 a total of 52,013, mainly hospitalized cases of dengue and 603 deaths have been registered with the Indonesian Ministry of Health. The overall case-fatality rate this year, particularly in Jakarta, has been lower than in previous years.

8 Apr 2004

More evidence needed to link symptoms like tics or behavioral problems to a strep infection

T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA

Researchers studying autoimmune diseases have found a molecular mechanism that explains how T-cells in lupus patients avoid apoptosis and are stimulated to produce antibodies against the patients own DNA.

1 Apr 2004

GenVec malaria vaccine initiative and the U.S. Naval Medical Research Center has announced partnership for malaria vaccine

GenVec, Inc., PATH's Malaria Vaccine Initiative (MVI), and the U.S. Naval Medical Research Center (NMRC) today announced a dynamic partnership to assess whether five malaria antigens, or proteins, can generate strong immune responses alone or in combination. This partnership will advance and expand the ongoing malaria vaccine development program between GenVec and NMRC. Malaria is one of the world's three leading infectious disease killers.

31 Mar 2004

Cryptosporidium parvum parasite could help to develope new therapies for the disease

Cryptosporidium parvum, an insidious, one-celled, waterborne parasite that lodges in the intestines of infected people and animals and for which there is currently no effective treatment, is missing key structures normally found in similar parasites, say researchers supported by the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health. The results of their genome sequencing project, could help scientists home in on new drug targets that may lead to therapies for the disease.

26 Mar 2004

Olopatadine nasal spray shown to minimise hay fever

Alcon announced today results from a Phase III clinical trial demonstrating that olopatadine nasal spray, a nasal formulation of its market leading ophthalmic anti-allergy product, Patanol(R) ophthalmic solution, reduced seasonal allergic rhinitis (SAR) symptoms compared to placebo.

22 Mar 2004

Clinical study - Diagnostic testing for epilepsy released

Bionomics Limited announced today the publication of its international clinical study involving patients with a form of epilepsy confined to early childhood in the scientific journal, Annals of Neurology. The publication details genes associated with a condition known as Benign Familial Neonatal Infantile Spasms (BFNIS), a condition in which infants experience seizures in the first few months of their life.

22 Mar 2004

Raptiva, 20 percent improvement in an individual's signs and symptoms of arthritis.

Genentech, Inc. and XOMA Ltd. today announced preliminary results of a randomized, placebo-controlled Phase II study with RAPTIVA™ (efalizumab) in 107 patients with psoriatic arthritis. The study did not reach statistical significance at 12 weeks (84 days) for the primary endpoint, ACR 20 response. An ACR 20 response indicates at least a 20 percent improvement in an individual's signs and symptoms of arthritis.

22 Mar 2004

New research may help prevent anthrax, bubonic plague and typhoid fever

The mechanism used by the bacteria that cause anthrax, bubonic plague and typhoid fever to avoid detection and destruction by the body’s normal immune response, leading to life-threatening bacterial infections, has been identified by researchers at the University of California, San Diego (UCSD) School of Medicine.

22 Mar 2004